Why the study?
Anthracycline-related cardiotoxicity causes significant morbidity and late mortality in childhood cancer survivors, but the optimal cardiac surveillance modality remains undefined.
Do advanced echocardiographic techniques (TDI, STE, 3D Echo) detect early subclinical myocardial changes in childhood cancer survivors treated with anthracyclines compared to controls?
Population
Childhood cancer survivors treated with anthracyclines and controls
Comparison
Childhood cancer survivors who received anthracycline therapy vs controls
Design
Observational comparative study
Follow-up
Mean 6.5 ± 2.8 years from end of therapy
Authors
Loading...
May support 3D echo and MPI for subclinical detection in survivors; hypothesis-generating and requires prospective outcome validation.
Do advanced echocardiographic techniques (TDI, STE, 3D Echo) detect early subclinical myocardial changes in childhood cancer survivors treated with anthracyclines compared to controls?
Three-dimensional echocardiography and myocardial performance index may detect subclinical myocardial dysfunction in childhood cancer survivors after anthracycline therapy even when standard 2D LVEF and strain are normal.
Sofia et al. (2021) studied this question.